AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein) General Information

Description

Rights to the development of a drug for opioid-induced constipation (OIC) treatment. The asset consists of the rights to sell and develop the drug in the European Union (EU), Iceland, Norway, Switzerland and Liechtenstein.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Primary Office
  • 2 Kingdom Street
  • London W2 6BD
  • England, United Kingdom

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein)‘s full profile, request access.

Request a free trial

AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein)‘s full profile, request access.

Request a free trial